Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott assay shows benefits in predicting heart attack risk

Abbott assay shows benefits in predicting heart attack risk

2nd August 2013

Abbott has reported data from a new study showing the benefits its Architect Stat hsTnI assay can provide in predicting a patient's risk of suffering a heart attack.

Presented at the annual meeting of the American Association for Clinical Chemistry, the study data showed that the hsTnI (high sensitive troponin-I) test can help doctors predict which patients presenting with symptoms of a heart attack – such as severe chest pain – are at a higher risk of having a heart attack 30 days later.

The team at Brigham and Women's Hospital compared the test to a leading alternative among 4,695 patients, finding that Abbott's product offered various benefits.

Architect Stat hsTnI is already commercially available in Europe, but remains restricted to research use only in the US.

Dr John Frels, divisional vice-president for diagnostics research at Abbott, said: "This study adds to the clinical evidence confirming the advantages of Abbott's high-sensitive troponin test to provide more insight to clinicians about which patients are at greater risk for a future heart attack as compared to contemporary tests."

According to its recent financial report, Abbott experienced a 4.2 percent year-on-year increase in sales during the second quarter of 2013.ADNFCR-8000103-ID-801620600-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.